Indoco Remedies

Indoco Remedies EV/OCF

The EV/OCF (Enterprise Value to Operating Cash Flow) of Indoco Remedies (INDOCO.NS) as of Oct 20, 2026 is 89.75. In the previous year, EV/OCF (Enterprise Value to Operating Cash Flow) was 102.00 — a change of -12.01% (lower).

EV/OCF

89.75

YoY

-12.01%

Last updated:

EV/OCF (Enterprise Value to Operating Cash Flow) of Indoco Remedies is 2026 89.75 . EV/OCF (Enterprise Value to Operating Cash Flow) of Indoco Remedies was 2025 102.00 . It decreases by -12.01% lower compared to the previous year.

The Indoco Remedies EV/OCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/OCF
Date
EV/OCF
Jan 1, 2019
16.15 INR
Jan 1, 2020
17.17 INR
Jan 1, 2021
25.81 INR
Jan 1, 2022
11.98 INR
Jan 1, 2023
12.23 INR
Jan 1, 2024
16.19 INR
Jan 1, 2025
102.00 INR
Jan 1, 2026
89.75 INR
The Indoco Remedies EV/OCF history
YEAREV/OCFYoY
89.75-12.01%
102.00+529.85%
16.19+32.38%
12.23+2.15%
11.98-53.59%
25.81+50.34%
17.17+6.27%
16.15-7.35%
17.43-24.32%
23.03+32.89%
17.33-2.14%
17.71-9.09%
19.48—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Indoco Remedies Stock analysis

What does Indoco Remedies do? Indoco Remedies Ltd. manufactures and markets formulations and active pharmaceutical ingredients, offering medicines across therapeutic categories like diabetology, respiratory, and women's health. Its product portfolio includes brands such as Cyclopam, Sensodent-K, Karvol Plus, and Rexidin M, targeting both domestic and international markets. The company serves healthcare providers and consumers through its extensive range of pharmaceutical products, with subsidiaries supporting its global operations. The firm's revenue streams derive from the sale of finished dosage forms and APIs, with key brands like Cital UTI and Kidodent catering to specific medical needs. International markets represent a significant segment, complementing domestic sales, while subsidiaries such as Indoco Remedies Czech sro and Indoco Remedies UK Limited facilitate regional distribution and market expansion. Products like Lignox A and Homide are positioned for niche therapeutic applications, driving demand among healthcare professionals and patients. Indoco Remedies is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Indoco Remedies stock

EV/OCF (Enterprise Value to Operating Cash Flow) of Indoco Remedies is 89.75 in 2026.

EV/OCF (Enterprise Value to Operating Cash Flow) of Indoco Remedies changed from 102.00 to 89.75, representing a -12.01% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EV/OCF (Enterprise Value to Operating Cash Flow) Indoco Remedies since 2006 – with annual values, charts, and detailed analysis.

EV/OCF compares enterprise value to operating cash flow, measuring how much investors pay per unit of cash generated from operations.

To evaluate EV/OCF (Enterprise Value to Operating Cash Flow)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/OCF (Enterprise Value to Operating Cash Flow).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/OCF (Enterprise Value to Operating Cash Flow)'s Indoco Remedies with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Valuation — Indoco Remedies

P/EP/SEV/EBITP/BP/CFP/FCFPEGEV/RevenueEV/EBITDAEV/FCFEarnings YieldFCF YieldMarket capitalizationEnterprise ValueForward P/EP/TBVShareholder YieldBuyback YieldDiv.-Adj. PEGEV/OCF

All Key Metrics — Indoco Remedies